AbbVie’s Rinvoq is a 15 mg, once-daily oral Janus kinase inhibitor (JAK) that is made to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Rinvoq helps regulate an overactive immune system to help stop an attack. The pharmaceutical agent works inside the cells to block certain signals that are known to cause inflammation.
In clinical studies, AbbVie said Rinvoq has shown to help reduce pain, swelling and stiffness to stop further joint damage.
Rinvoq’s common side effects include upper respiratory tract infections like common cold and sinus infections, nausea, cough and fever.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.